Kees Melief, CSO of ISA Pharmaceuticals, receives prestigious Coley Award

June 05, 2009

FOR IMMEDIATE RELEASE Scientific & Corporate Leaders in Immunology, Tumor Immunology to be Honored at Cancer Research Institute 23rd Annual Awards Dinner 2009 Grace and Coley Award Winners Announced

May 29, 2009 -- The Cancer Research Institute, Inc. (CRI), a nonprofit organization dedicated to the development of immunological treatment, control, and prevention of cancer, announced today the winners of the 2009 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. Cornelis J.M. Melief, M.D., Ph.D., CSO of ISA Pharmaceuticals and professor at Leiden University Medical Center in The Netherlands, will receive the William B. Coley Award for Distinguished Research in Tumor Immunology for his novel insights into the relationship between tumors and the host’s immune system, in particular his description of certain key mechanisms of cytotoxic T lymphocyte recognition of tumor antigen and their subsequent activation, and for his development of innovative therapies that have been applied in the clinic or are being translated in the clinic based on improved insights into cell-mediated immunity.

About the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology
This award was established in 1975 in honor of Dr. William B. Coley, a pioneer of cancer immunotherapy, whose daughter Helen Coley Nauts (1907-2001) founded the Cancer Research Institute. Award winners are nominated by CRI’s Scientific Advisory Council, the Academy of Cancer Immunology, and former Coley Award winners, including: Michael J. Bevan (2008), HHMI, University of Washington; Jeffrey V. Ravetch (2007), The Rockefeller University; Ian H. Frazer (2006), University of Queensland; James P. Allison (2005), The Ludwig Center/Memorial Sloan-Kettering Cancer Center; and Robert D. Schreiber (2001), Washington University School of Medicine.

About the Cancer Research Institute
The Cancer Research Institute (CRI) is the world’s only non-profit organization dedicated exclusively to the support and coordination of scientific and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. Guided by a world-renowned Scientific Advisory Council that includes five Nobel Prize winners and thirty members of the National Academy of Sciences, CRI supports cutting-edge cancer research at top medical centers and universities throughout the world. The Cancer Research Institute is ushering in a new era of scientific progress, hastening the discovery of effective cancer vaccines and other immune-based therapies that are providing new hope to cancer patients. www.cancerresearch.org

About ISA
ISA Pharmaceuticals is dedicated to fighting cancer and infectious diseases by providing novel ways based on its proprietary SLP® technology to activate and employ the patient's own immune system. Its most advanced product is a therapeutic vaccine against HPV-induced lesions. The company was founded in 2004 by Aglaia Oncology Fund and has its roots in the ground breaking research performed by the group of Professor Cornelis Melief. R&D is performed in close collaboration with the Leiden University Medical Center, the Netherlands. For more information about ISA, please visit www.isa-pharma.com.

Contact details: Gerard Platenburg, CEO, platenburg@isa-pharma.com

Home > News & Events > Kees Melief, CSO of ISA Pharmaceuticals, receiv...

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds